Crinetics Pharmaceuticals, Inc. 8-K Filing
Ticker: CRNX · Form: 8-K · Filed: Apr 4, 2024 · CIK: 1658247
| Field | Detail |
|---|---|
| Company | Crinetics Pharmaceuticals, Inc. (CRNX) |
| Form Type | 8-K |
| Filed Date | Apr 4, 2024 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Crinetics Pharmaceuticals, Inc. (ticker: CRNX) to the SEC on Apr 4, 2024.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select).
How long is this filing?
Crinetics Pharmaceuticals, Inc.'s 8-K filing is 2 pages with approximately 696 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 696 words · 3 min read · ~2 pages · Grade level 13 · Accepted 2024-04-04 16:52:02
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select
Filing Documents
- d819564d8k.htm (8-K) — 23KB
- 0001193125-24-087326.txt ( ) — 139KB
- crnx-20240329.xsd (EX-101.SCH) — 3KB
- crnx-20240329_lab.xml (EX-101.LAB) — 17KB
- crnx-20240329_pre.xml (EX-101.PRE) — 11KB
- d819564d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date:April 4, 2024 By: /s/ R. Scott Struthers, Ph. D. R. Scott Struthers, Ph. D. President and Chief Executive Officer